KCRS26 Program

Overview of Artificial Intelligence in Cancer Genomics
Sylvan Baca, Dana-Farber Cancer Institute

Incorporating Artificial Intelligence into Pathology
Julie Stein Deutsch, Johns Hopkins Medicine

The Role of Radiomics and Artificial Intelligence in Kidney Cancer
Andrew Smith, St. Jude Children’s Research Hospital

Trial Discovery for Every Cancer Patient
Hari Kasi, Almara, Inc.

Academy of Kidney Cancer Investigators Impact
Abhishek Chakraborty, Cleveland Clinic

Kidney Cancer Research Consortium Impact
Eric Jonasch, MD Anderson Cancer Center

UT Southwestern Medical Center SPORE Impact
James Brugarolas, UT Southwestern Medical Center

Dana-Farber/Harvard Cancer Center SPORE Impact
David McDermott, Beth Israel Deaconess Medical Center

Moderated Panel Discussion
All presenters plus Toni Choueiri, Dana-Farber Cancer Institute

Pembrolizumab Plus Belzutifan Versus Pembrolizumab Plus Placebo as Adjuvant Therapy for Renal Cell Carcinoma: Patient-Reported Outcomes in LITESPARK-022
Thomas Powles, Barts Cancer Center

Relationships Between Plasma KIM-1 Levels, Peripheral Immune Profiles and Disease-Free Survival Outcomes in the TransRAMPART Study
James Jones, University of Cambridge

Safety Profile of Casdatifan Monotherapy in Patients with Clear Cell Renal Cell Carcinoma: Pooled Analysis of the ARC-20 Study (NCT05536141)
Rana McKay, University of California, San Diego

Baseline and Early On‑Treatment Plasma Kidney Injury Molecule-1 (KIM‑1) Levels Are Associated with Outcomes in Advanced Renal Cell Carcinoma (aRCC)
Wenxin Xu, Dana-Farber Cancer Institute

Stereotactic Body Radiation Therapy Enriches Mediators of Humoral Immune Activity in Metastatic Renal Cell Carcinoma
Nicholas Salgia, Roswell Park Comprehensive Cancer Center

Antitumor Activity of 177Lu-PSMA-617 in PSMA-Positive Metastatic Clear Cell Renal Cell Carcinoma (ccRCC): Results from a Phase 2 Trial (LASER)
Praful Ravi, Dana-Farber Cancer Institute

Mitochondrial DNA Mutations Phenocopy VHL Loss to Drive Non-Clear Cell RCC
Ziad Bakouny, Memorial Sloan Kettering Cancer Center

Single Cell Transcriptomic Investigation of Renal Cell Carcinoma (RCC) Reveals Tissue Resident Memory Exhausted CD8+ T Cell Signature Associated with Resistance to Immune Checkpoint Inhibition (ICI)
Rishabh Rout, Yale School of Medicine

CD8+ T Cells and Clinical Outcomes from the CYTO Reductive Surgery in Kidney Cancer Plus Immunotherapy and Targeted Kinase Inhibition (Cyto-KIK) Trial
Karie Runcie, Columbia University Herbert Irving Comprehensive Cancer Center

Targeting the Microbiome in Cancer Immunotherapies
Bertrand Routy, University of Montreal

Ivonescimab: A Novel First-in-Class PD-1 x VEGF Bispecific Antibody
Fiona An, Summit Therapeutics

The Cancer Dark Proteome: A Rich Source of Novel Tumor Antigens
Will Freed-Pastor, Dana-Farber Cancer Institute

AI Protein Design
John Connolly, Parker Institute for Cancer Immunotherapy

Code to Clinic: Translating Single-Cell, Spatial Genomics, and ML/AI into RCC Brain Metastases Trials and Patient Care
Elshad Hasanov, The Ohio State University

Translational Insights into RCC Brain Metastases
Roy Elias, Johns Hopkins University

Learning from Other Diseases: CNS Success Stories
Harriet Kluger, Yale School of Medicine

Radiosurgery for Brain Metastases: Balancing the Therapeutic Ratio with Novel Systemic Therapies
Raj Singh, Baptist Health South Florida Lynn Cancer Institute

PF-08634404 (SSGJ-707), a Tetravalent PD-1/VEGF Bispecific Antibody for the Treatment of Renal Cell Carcinoma (NCT07227415)
Toni Choueiri, Dana-Farber Cancer Institute

A Phase II Study of Total Consolidative Metastasis-and-Primary Directed Therapy for Renal Cell Carcinoma (NCT06770855)
Henry Litt, University of Pennsylvania

Phase II Study of Cemiplimab ± Fianlimab Following SBRT for Oligometastatic Clear-Cell RCC (LAG-BOOST) (NCT07223541)
Abhirami Das, The University of Oklahoma College of Medicine

PRISM: Phase 1b of Retifanlimab and Ruxolitinib in Solid Malignancies Progressing on Prior Checkpoint Inhibition (NCT07219576)
Rana McKay, University of California, San Diego

A Phase 1b/2 Study of Abemaciclib Plus Cabozantinib in Immune Checkpoint Blockade-Pretreated Metastatic Clear Cell Renal Cell Carcinoma and Translocation-Associated Renal Cell Carcinoma (NCT06835972)
Sahil Doshi, Memorial Sloan Kettering Cancer Center

Phase II Trial of Sacituzumab Tirumotecan in Patients with SMARCB1-Deficient Renal Medullary Carcinoma Previously Treated with at Least One Prior Line of Therapy: STaRMC Trial (NCT07438626)
Pavlos Msaouel, MD Anderson Cancer Center

AACR Highlights
Tian Zhang, UT Southwestern Medical Center

ASCO Highlights
Michael Serzan, Dana-Farber Cancer Institute

ESMO Highlights
Laurence Albiges, Gustave Roussy

ASCO GU Highlights
Katy Beckermann, Tennessee Oncology

Outcomes of Patients with Renal Cell Carcinoma Achieving Pathologic Complete or Major Response After Consolidative Nephrectomy Following Immune Checkpoint Inhibitor Therapy
Paulo Siqueira do Amaral, Northwestern University

Long-Term Follow-Up from the OMNIVORE Trial: Response-Adaptive Nivolumab and Ipilimumab in Advanced Renal Cell Carcinoma (NCT03652142)
Michael Serzan, Dana-Farber Cancer Institute

Farnesyl Transferase Inhibitor (FTI) Darlifarnib Combined with Cabozantinib in Renal Cell Carcinoma (RCC): Updated Phase 1a Results from FIT-001
Adanma Ayanambakkam, Oklahoma University Health

Molecular and Clinical Characterization of Early-Onset Renal Cell Carcinoma (eoRCC): A Real-World Multi-Omics Analysis
Hedyeh Ebrahimi, Beth Israel Deaconess Medical Center

Evaluation of the Effects of the HIF-2α Inhibitor Belzutifan on T-cell–Mediated Cytotoxicity in Renal Cell Carcinoma
Soki Kashima, Yale School of Medicine

Defining Systemic and Tumor-Intrinsic Biomarkers of Immune Suppression in Renal Cell Carcinoma
Giuliana Mognol, University of California San Diego

ABBV-CLS-484: A Novel Oral PTPN2/1 Inhibitor for Cancer Immunotherapy
Hans Hammers, UT Southwestern Medical Center

Preclinical Study of Anti-CAIX/CD70 DFIR CAR-T Cell Therapy Secreting Anti-PD-1/CTLA-4 Bispecific Payload for Advanced Clear Cell Renal Cell Carcinoma Treatment
Yufei Wang, Dana-Farber Cancer Institute

Prediction of Immune-Related Adverse Events (irAEs) with Hematologic Markers in Patients Receiving First-Line Immune Checkpoint Inhibitor (ICI)-Based Therapy in Metastatic Renal Cell Carcinoma (mRCC)
Rahul Winayak, City of Hope Comprehensive Cancer Center

Dissecting ARNT Expression Patterns in RCC and Association with Outcomes
Yu-Wei Chen, University of California San Diego